JP2009501776A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009501776A5 JP2009501776A5 JP2008522065A JP2008522065A JP2009501776A5 JP 2009501776 A5 JP2009501776 A5 JP 2009501776A5 JP 2008522065 A JP2008522065 A JP 2008522065A JP 2008522065 A JP2008522065 A JP 2008522065A JP 2009501776 A5 JP2009501776 A5 JP 2009501776A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- compound
- formula
- benzyl
- free fatty
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 claims 31
- 235000021588 free fatty acids Nutrition 0.000 claims 18
- 125000000217 alkyl group Chemical group 0.000 claims 14
- 125000003118 aryl group Chemical group 0.000 claims 13
- 125000001072 heteroaryl group Chemical group 0.000 claims 12
- 230000010261 cell growth Effects 0.000 claims 11
- 239000003814 drug Substances 0.000 claims 9
- 125000005843 halogen group Chemical group 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- 208000024891 symptom Diseases 0.000 claims 7
- 210000004027 cell Anatomy 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000012453 solvate Substances 0.000 claims 6
- 239000002671 adjuvant Substances 0.000 claims 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 5
- 239000003085 diluting agent Substances 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 201000008980 hyperinsulinism Diseases 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 238000002360 preparation method Methods 0.000 claims 4
- 238000012360 testing method Methods 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 3
- MGJFLAHLODASKL-UHFFFAOYSA-N 2-(4-chloroanilino)-5-[[3-(trifluoromethyl)phenyl]methyl]-1,3-thiazol-4-one Chemical compound FC(F)(F)C1=CC=CC(CC2C(N=C(NC=3C=CC(Cl)=CC=3)S2)=O)=C1 MGJFLAHLODASKL-UHFFFAOYSA-N 0.000 claims 2
- LKJFEVJLZCHMNR-UHFFFAOYSA-N 2-(4-methylanilino)-5-[[3-(trifluoromethyl)phenyl]methyl]-1,3-thiazol-4-one Chemical compound C1=CC(C)=CC=C1NC(S1)=NC(=O)C1CC1=CC=CC(C(F)(F)F)=C1 LKJFEVJLZCHMNR-UHFFFAOYSA-N 0.000 claims 2
- -1 5- [3- (trifluoromethyl) benzyl] -4-oxothiazolidine-2-yl Phenyl Chemical group 0.000 claims 2
- OJOXIPILLXOGHW-UHFFFAOYSA-N 5-[(4-fluorophenyl)methyl]-2-(pyridin-2-ylamino)-1,3-thiazol-4-one Chemical compound C1=CC(F)=CC=C1CC1C(=O)N=C(NC=2N=CC=CC=2)S1 OJOXIPILLXOGHW-UHFFFAOYSA-N 0.000 claims 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 claims 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 210000003734 kidney Anatomy 0.000 claims 2
- 238000012216 screening Methods 0.000 claims 2
- 102000004277 11-beta-hydroxysteroid dehydrogenases Human genes 0.000 claims 1
- 108090000874 11-beta-hydroxysteroid dehydrogenases Proteins 0.000 claims 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 claims 1
- MEEOKGMAKDGKDE-UHFFFAOYSA-N 2-(2,4-dichloroanilino)-5-[[3-(trifluoromethyl)phenyl]methyl]-1,3-thiazol-4-one Chemical compound FC(F)(F)C1=CC=CC(CC2C(NC(S2)=NC=2C(=CC(Cl)=CC=2)Cl)=O)=C1 MEEOKGMAKDGKDE-UHFFFAOYSA-N 0.000 claims 1
- XCZIHERGIOEZRO-UHFFFAOYSA-N 2-(3,4-dichloroanilino)-5-[[3-(trifluoromethyl)phenyl]methyl]-1,3-thiazol-4-one Chemical compound FC(F)(F)C1=CC=CC(CC2C(NC(S2)=NC=2C=C(Cl)C(Cl)=CC=2)=O)=C1 XCZIHERGIOEZRO-UHFFFAOYSA-N 0.000 claims 1
- LCBASURTTNEAPL-UHFFFAOYSA-N 2-(4-chloroanilino)-5-[(4-methylphenyl)methyl]-1,3-thiazol-4-one Chemical compound C1=CC(C)=CC=C1CC1C(=O)N=C(NC=2C=CC(Cl)=CC=2)S1 LCBASURTTNEAPL-UHFFFAOYSA-N 0.000 claims 1
- CYCZYGRIZJUNBZ-UHFFFAOYSA-N 2-(4-methoxyanilino)-5-[[3-(trifluoromethyl)phenyl]methyl]-1,3-thiazol-4-one Chemical compound C1=CC(OC)=CC=C1N=C1SC(CC=2C=C(C=CC=2)C(F)(F)F)C(=O)N1 CYCZYGRIZJUNBZ-UHFFFAOYSA-N 0.000 claims 1
- ACQMGTBEKGXGJU-UHFFFAOYSA-N 2-(4-propan-2-ylanilino)-5-[[3-(trifluoromethyl)phenyl]methyl]-1,3-thiazol-4-one Chemical compound C1=CC(C(C)C)=CC=C1N=C1SC(CC=2C=C(C=CC=2)C(F)(F)F)C(=O)N1 ACQMGTBEKGXGJU-UHFFFAOYSA-N 0.000 claims 1
- DXTMCFZBFJNDOP-UHFFFAOYSA-N 2-anilino-5-[[3-(trifluoromethyl)phenyl]methyl]-1,3-thiazol-4-one Chemical compound FC(F)(F)C1=CC=CC(CC2C(N=C(NC=3C=CC=CC=3)S2)=O)=C1 DXTMCFZBFJNDOP-UHFFFAOYSA-N 0.000 claims 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- GWTUAJSBEZTXJX-UHFFFAOYSA-N 3-methyl-2-(4-methylphenyl)imino-5-[[3-(trifluoromethyl)phenyl]methyl]-1,3-thiazolidin-4-one Chemical compound S1C(=NC=2C=CC(C)=CC=2)N(C)C(=O)C1CC1=CC=CC(C(F)(F)F)=C1 GWTUAJSBEZTXJX-UHFFFAOYSA-N 0.000 claims 1
- BLDISNZVRORTLZ-UHFFFAOYSA-N 4-[[[4-(2-hydroxyphenyl)-5-[(2-methoxyphenyl)methyl]-1,3-thiazol-2-yl]amino]methyl]benzoic acid Chemical compound COC1=CC=CC=C1CC1=C(C=2C(=CC=CC=2)O)N=C(NCC=2C=CC(=CC=2)C(O)=O)S1 BLDISNZVRORTLZ-UHFFFAOYSA-N 0.000 claims 1
- XADDQYPFOIKDIZ-UHFFFAOYSA-N 4-[[[5-[(2,3-difluorophenyl)methyl]-4-(2-hydroxyphenyl)-1,3-thiazol-2-yl]amino]methyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1CNC(S1)=NC(C=2C(=CC=CC=2)O)=C1CC1=CC=CC(F)=C1F XADDQYPFOIKDIZ-UHFFFAOYSA-N 0.000 claims 1
- SCQQRZGNOYUJMM-UHFFFAOYSA-N 4-[[[5-[(2,6-difluorophenyl)methyl]-4-(2-hydroxyphenyl)-1,3-thiazol-2-yl]amino]methyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1CNC(S1)=NC(C=2C(=CC=CC=2)O)=C1CC1=C(F)C=CC=C1F SCQQRZGNOYUJMM-UHFFFAOYSA-N 0.000 claims 1
- ZRQDEHTUTQHZPU-UHFFFAOYSA-N 4-[[[5-[(2,6-difluorophenyl)methyl]-4-(3-hydroxyphenyl)-1,3-thiazol-2-yl]amino]methyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1CNC(S1)=NC(C=2C=C(O)C=CC=2)=C1CC1=C(F)C=CC=C1F ZRQDEHTUTQHZPU-UHFFFAOYSA-N 0.000 claims 1
- KXPAJSAIUIKHHH-UHFFFAOYSA-N 4-chloro-n-[4-oxo-5-[[3-(trifluoromethyl)phenyl]methyl]-1,3-thiazol-2-yl]benzamide Chemical compound FC(F)(F)C1=CC=CC(CC2C(NC(S2)=NC(=O)C=2C=CC(Cl)=CC=2)=O)=C1 KXPAJSAIUIKHHH-UHFFFAOYSA-N 0.000 claims 1
- HVTYXFRFLWCHNY-UHFFFAOYSA-N 4-chloro-n-[4-oxo-5-[[3-(trifluoromethyl)phenyl]methyl]-1,3-thiazol-2-yl]benzenesulfonamide Chemical compound FC(F)(F)C1=CC=CC(CC2C(NC(S2)=NS(=O)(=O)C=2C=CC(Cl)=CC=2)=O)=C1 HVTYXFRFLWCHNY-UHFFFAOYSA-N 0.000 claims 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 claims 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 claims 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108010011459 Exenatide Proteins 0.000 claims 1
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 claims 1
- 208000004930 Fatty Liver Diseases 0.000 claims 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 claims 1
- 108010004460 Gastric Inhibitory Polypeptide Proteins 0.000 claims 1
- 102100039994 Gastric inhibitory polypeptide Human genes 0.000 claims 1
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 claims 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims 1
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 claims 1
- 208000002705 Glucose Intolerance Diseases 0.000 claims 1
- 206010019708 Hepatic steatosis Diseases 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 229940122199 Insulin secretagogue Drugs 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 229940126033 PPAR agonist Drugs 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 210000000577 adipose tissue Anatomy 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 claims 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 claims 1
- 230000022131 cell cycle Effects 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims 1
- 229960004544 cortisone Drugs 0.000 claims 1
- 230000000139 costimulatory effect Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 238000011156 evaluation Methods 0.000 claims 1
- 229960001519 exenatide Drugs 0.000 claims 1
- 208000010706 fatty liver disease Diseases 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 claims 1
- 229960000890 hydrocortisone Drugs 0.000 claims 1
- 238000010348 incorporation Methods 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 230000004068 intracellular signaling Effects 0.000 claims 1
- 210000005228 liver tissue Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 230000002503 metabolic effect Effects 0.000 claims 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims 1
- 229960003105 metformin Drugs 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 239000002307 peroxisome proliferator activated receptor agonist Substances 0.000 claims 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims 1
- 201000009104 prediabetes syndrome Diseases 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 231100000240 steatosis hepatitis Toxicity 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 125000000547 substituted alkyl group Chemical group 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 229940104230 thymidine Drugs 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US59562005P | 2005-07-21 | 2005-07-21 | |
| SE0501721 | 2005-07-21 | ||
| US74442206P | 2006-04-07 | 2006-04-07 | |
| PCT/GB2006/002743 WO2007010281A2 (en) | 2005-07-21 | 2006-07-21 | Use of thiazole derivatives and analogues in disorders caused by free fatty acids |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009501776A JP2009501776A (ja) | 2009-01-22 |
| JP2009501776A5 true JP2009501776A5 (cg-RX-API-DMAC10.html) | 2009-09-10 |
Family
ID=37669179
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008522065A Withdrawn JP2009501776A (ja) | 2005-07-21 | 2006-07-21 | 遊離脂肪酸に起因した障害におけるチアゾール誘導体およびアナログの使用 |
| JP2008522062A Withdrawn JP2009501775A (ja) | 2005-07-21 | 2006-07-21 | 癌治療におけるチアゾール誘導体およびアナログの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008522062A Withdrawn JP2009501775A (ja) | 2005-07-21 | 2006-07-21 | 癌治療におけるチアゾール誘導体およびアナログの使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20090156644A1 (cg-RX-API-DMAC10.html) |
| EP (2) | EP1906956A2 (cg-RX-API-DMAC10.html) |
| JP (2) | JP2009501776A (cg-RX-API-DMAC10.html) |
| KR (2) | KR20080034436A (cg-RX-API-DMAC10.html) |
| AU (2) | AU2006271375A1 (cg-RX-API-DMAC10.html) |
| CA (2) | CA2614327A1 (cg-RX-API-DMAC10.html) |
| EA (2) | EA200800302A1 (cg-RX-API-DMAC10.html) |
| IL (2) | IL188031A0 (cg-RX-API-DMAC10.html) |
| NO (2) | NO20076333L (cg-RX-API-DMAC10.html) |
| WO (2) | WO2007010273A2 (cg-RX-API-DMAC10.html) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102005024012A1 (de) * | 2005-05-20 | 2006-11-23 | Grünenthal GmbH | Verwendung von 2,5-disubstituierten Thiazol-4-on-Derivaten in Arzneimitteln |
| WO2008065409A2 (en) * | 2006-12-01 | 2008-06-05 | Betagenon Ab | Combination for use in the treatment of cancer, comprising tamoxifen or an aromatase inhibitor |
| WO2008090327A1 (en) * | 2007-01-22 | 2008-07-31 | Betagenon Ab | New combination for use in the treatment of cancer |
| US20080234332A1 (en) * | 2007-03-20 | 2008-09-25 | Xiong Cai | Raf kinase inhibitors containing a zinc binding moiety |
| CN101274918A (zh) * | 2007-03-30 | 2008-10-01 | 中国科学院上海药物研究所 | 一类取代五元杂环化合物,其制备方法和医学用途 |
| AR067769A1 (es) * | 2007-08-03 | 2009-10-21 | Betagenon Ab | Derivado de ditiazol para el tratamiento del cancer |
| KR20100090250A (ko) | 2007-10-09 | 2010-08-13 | 메르크 파텐트 게엠베하 | 글루코키나제 활성체로서 유용한 피리딘 유도체 |
| CA2743756A1 (en) * | 2007-11-15 | 2009-05-22 | Musc Foundation For Research Development | Inhibitors of pim protein kinases, compositions, and methods for treating cancer |
| KR100998572B1 (ko) * | 2007-12-14 | 2010-12-07 | 한국생명공학연구원 | 단백질 포스파타제의 활성을 억제하는 페닐아미노티아졸론유도체 또는 이의 약학적으로 허용가능한 염을유효성분으로 함유하는 암 예방 및 치료용 조성물 |
| WO2010073011A2 (en) | 2008-12-23 | 2010-07-01 | Betagenon Ab | Compounds useful as medicaments |
| WO2010086613A1 (en) | 2009-01-30 | 2010-08-05 | Betagenon Ab | Compounds useful as inhibitors as ampk |
| AU2010270030B2 (en) | 2009-07-08 | 2015-12-24 | Baltic Bio Ab | 1, 2, 4-thiazolidin-3-one derivatives and their use in the treatment of cancer |
| WO2011079036A1 (en) * | 2009-12-22 | 2011-06-30 | The Translational Genomics Research Institute | Benzamide derivatives |
| WO2012118935A1 (en) | 2011-03-03 | 2012-09-07 | Proteotech Inc | Compounds for the treatment of neurodegenerative diseases |
| EP2760856B1 (en) * | 2011-09-30 | 2016-09-14 | Bristol-Myers Squibb Company | Selective nr2b antagonists |
| WO2013108026A1 (en) | 2012-01-17 | 2013-07-25 | Baltic Bio Ab | Thiadiazolone derivatives useful in the treatment of diabetes |
| CN104059060B (zh) * | 2014-05-30 | 2017-08-01 | 西安交通大学 | 一种5‑(1h‑吲哚‑3‑亚甲基)‑1,3‑噻唑烷‑4‑酮类衍生物及其合成方法和应用 |
| BR112022002815A2 (pt) * | 2019-08-15 | 2022-05-10 | Bayer Ag | Método para preparar 2-(fenilimino)-3-alquil-1,3-tiazolidin- 4-onas |
| GB202112529D0 (en) * | 2021-09-02 | 2021-10-20 | Betagenon Bio Ab | New compounds |
| EP4448492B1 (en) | 2021-12-17 | 2026-03-04 | Reglagene, Inc. | Compositions and methods of making and using small molecules in the treatment of cancer |
| JP7894535B2 (ja) | 2023-02-28 | 2026-07-23 | レグラジーン、インコーポレイテッド | 健康状態の治療のための小分子を作製および使用するための組成物および方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3345374A (en) * | 1962-09-04 | 1967-10-03 | Bayer Ag | Certain oxathiazole and dithiazole derivatives |
| US3671537A (en) * | 1969-06-05 | 1972-06-20 | Gyogyszerkutato Intezet | Certain 3-(2,6-dichlorophenyl)-2-iminothiazolidines |
| US4103018A (en) * | 1976-10-12 | 1978-07-25 | Schering Corporation | 2-[4-(Polyhalo-2-hydroxy-2-propyl)anilino]-2-oxazolin-4-ones and thiazolin-4-ones corresponding thereto |
| HU191408B (en) * | 1984-04-25 | 1987-02-27 | Egis Gyogyszergyar,Hu | Process for preparing new imino-thiazolidine derivatives |
| DD246541A1 (de) * | 1986-01-27 | 1987-06-10 | Univ Halle Wittenberg | Verfahren zur herstellung von 5-arylidenthiazolidin-4-onen |
| DD270072A1 (de) * | 1988-03-14 | 1989-07-19 | Univ Halle Wittenberg | Verfahren zur herstellung von 5-aryliden- hoch 2-thiazolin-4-onen |
| US6353006B1 (en) * | 1999-01-14 | 2002-03-05 | Bayer Corporation | Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents |
| US20040152667A1 (en) * | 2002-10-23 | 2004-08-05 | Hauske James R. | 4-Alkenylthiazoles comprising epoxide functionality, and methods of use thereof |
| WO2005082363A1 (en) * | 2004-02-20 | 2005-09-09 | Board Of Regents, The University Of Texas System | Thiazolone compounds for treatment of cancer |
| CN1972937A (zh) * | 2004-04-30 | 2007-05-30 | 先灵公司 | 神经肽受体调节剂 |
| RU2007103709A (ru) * | 2004-07-01 | 2008-08-10 | Ф.Хоффманн-Ля Рош Аг (Ch) | Тиазолинонхинолины |
| EP1776112A4 (en) * | 2004-08-10 | 2009-11-25 | Exelixis Inc | HETEROCYCLIC COMPOUNDS AS PHARMACEUTICAL AGENTS |
| WO2006040050A1 (en) * | 2004-10-14 | 2006-04-20 | F.Hoffmann-La Roche Ag | Quinazolinylmethylene thiazolinones as cdk1 inhibitors |
| CN100525929C (zh) * | 2005-04-20 | 2009-08-12 | 郭文礼 | 喷水枪出水控制装置 |
| CA2614098A1 (en) * | 2005-07-04 | 2007-01-11 | Dr. Reddy's Laboratories Ltd. | Thiazoles derivatives as ampk activator |
-
2006
- 2006-07-21 US US11/989,029 patent/US20090156644A1/en not_active Abandoned
- 2006-07-21 AU AU2006271375A patent/AU2006271375A1/en not_active Abandoned
- 2006-07-21 KR KR1020087001174A patent/KR20080034436A/ko not_active Withdrawn
- 2006-07-21 CA CA002614327A patent/CA2614327A1/en not_active Abandoned
- 2006-07-21 WO PCT/GB2006/002730 patent/WO2007010273A2/en not_active Ceased
- 2006-07-21 US US11/989,001 patent/US20090136472A1/en not_active Abandoned
- 2006-07-21 EA EA200800302A patent/EA200800302A1/ru unknown
- 2006-07-21 KR KR1020087001175A patent/KR20080032096A/ko not_active Withdrawn
- 2006-07-21 JP JP2008522065A patent/JP2009501776A/ja not_active Withdrawn
- 2006-07-21 EP EP06765072A patent/EP1906956A2/en not_active Withdrawn
- 2006-07-21 EP EP06765059A patent/EP1906955A2/en not_active Withdrawn
- 2006-07-21 JP JP2008522062A patent/JP2009501775A/ja not_active Withdrawn
- 2006-07-21 AU AU2006271383A patent/AU2006271383A1/en not_active Abandoned
- 2006-07-21 WO PCT/GB2006/002743 patent/WO2007010281A2/en not_active Ceased
- 2006-07-21 CA CA002615752A patent/CA2615752A1/en not_active Abandoned
- 2006-07-21 EA EA200800303A patent/EA200800303A1/ru unknown
-
2007
- 2007-12-10 IL IL188031A patent/IL188031A0/en unknown
- 2007-12-11 NO NO20076333A patent/NO20076333L/no not_active Application Discontinuation
- 2007-12-13 NO NO20076420A patent/NO20076420L/no not_active Application Discontinuation
- 2007-12-16 IL IL188163A patent/IL188163A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2038265T3 (en) | Inhibitors of human protein tyrosine phosphatase and methods of use | |
| Kurtz et al. | Next generation multifunctional angiotensin receptor blockers | |
| JP2009501775A5 (cg-RX-API-DMAC10.html) | ||
| JP2009504599A (ja) | Ｄｐｐ−ｉｖ阻害剤を含有する医薬組成物 | |
| ZA200406068B (en) | Thiazole and oxazole derivatives which modulate PPAR activity. | |
| US20180117013A1 (en) | Methods of treating liver disease using indane acetic acid derivatives | |
| JP2006516251A5 (cg-RX-API-DMAC10.html) | ||
| US20110092517A1 (en) | Use of PPAR Delta Ligands for the Treatment or Prevention of Inflammation or Energy Metabolism/Production Related Diseases | |
| MXPA05009789A (es) | Combinacion de un antagonista del receptor de aldosterona y un agente antidiabetico. | |
| JP5968927B2 (ja) | 高血圧と代謝症候群の治療に用いられる薬物組成物及びその応用 | |
| JP2000273043A (ja) | ピオグリタゾンを含有する耐糖能不全治療剤 | |
| KR20080032096A (ko) | 유리지방산에 의해 야기되는 질환에 사용되는 티아졸유도체 및 유사체의 용도 | |
| US20080207710A1 (en) | Insulin Secretagogue Drugs | |
| JP2007538102A5 (cg-RX-API-DMAC10.html) | ||
| CN101506180B (zh) | 人蛋白酪氨酸磷酸酶抑制剂及使用方法 | |
| RU2435763C2 (ru) | Ингибиторы тирозинфосфатазы белка человека и способы применения | |
| JP2005514399A (ja) | ＰＰＡＲγアクチベーターの投薬法 | |
| KR19990036290A (ko) | 비인슐린 의존성 진성 당뇨병 환자에 대한 외인성 인슐린 투여량의 감소 방법 | |
| CN1167416C (zh) | 利用葡萄糖摄入增强剂制备减小心脏缺血后损伤的药物 | |
| JP2003063993A (ja) | 医薬組成物 | |
| KR100697097B1 (ko) | 당뇨병 예방 또는 치료용 약학 조성물 | |
| CN1592620A (zh) | 与心脏胰岛素抵抗相关的疾病的治疗和预防方法 | |
| Dev | API SYNTHESIS INTERNATIONAL | |
| Davies et al. | Rivoglitazone hydrochloride | |
| JP2009234946A (ja) | 併用医薬 |